Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 46, 2011, Pages

  Farrow, Emily G ^a   Yu, Xijie ^b   Summers, Lelia J ^a   Davis, Siobhan I ^a   Fleet, James C ^c   Allen, Matthew R ^a   Robling, Alexander G ^a   Stayrook, Keith R ^a   Jideonwo, Victoria ^a   Magers, Martin J ^a   Garringer, Holly J ^a   Vidal, Ruben ^a   Chan, Rebecca J ^a   Goodwin, Charles B ^a   Hui, Siu L ^a   Peacock, Munro ^a   White, Kenneth E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SICHUAN UNIVERSITY   (China)

^c PURDUE UNIVERSITY   (United States)

Author keywords

klotho; Anemia; FGF 23; Osteocyte

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; IRON; MESSENGER RNA; PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENE MUTATION; HYPOPHOSPHATEMIC RICKETS; IN VITRO STUDY; IRON CHELATION; IRON DEFICIENCY; IRON RESTRICTION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PHOSPHATE METABOLISM; PREGNANCY; PRIORITY JOURNAL; PUBERTY; WILD TYPE;

ANEMIA, IRON-DEFICIENCY; ANIMALS; FEMALE; FIBROBLAST GROWTH FACTORS; GENE-ENVIRONMENT INTERACTION; GLUCURONIDASE; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; IRON; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; OSTEOCYTES; OSTEOMALACIA; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RATS;

MUS;

EID: 81755163635     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1110905108     Document Type: Article

References (48)

1. Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674-681. (Pubitemid 27068650)
2. ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348.
3. White KE, et al. (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086. (Pubitemid 33070451)
4. Shimada T, et al. (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182. (Pubitemid 34809892)
5. Urakawa I, et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774. (Pubitemid 44949607)
6. Kurosu H, et al. (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120-6123. (Pubitemid 43847540)
7. Shimada T, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505. (Pubitemid 32488266)
8. Feng JQ, et al. (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315. (Pubitemid 44646294)
9. Lorenz-Depiereux B, et al. (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250. (Pubitemid 44646286)
10. Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 7:287-295.
11. Imel EA, Hui SL, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520-526. (Pubitemid 47457428)
12. Breymann C, Honegger C, Holzgreve W, Surbek D (2010) Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet 282:577-580.
13. Gribaa M, et al. (2010) An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 28:111-115.
14. Imel EA, et al. (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab, in press.
15. Durham BH, Joseph F, Bailey LM, Fraser WD (2007) The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 44:463-466. (Pubitemid 351724655)
16. Ohira Y, Gill SL (1983) Effects of dietary iron deficiency on muscle fiber characteristics and whole-body distribution of hemoglobin in mice. J Nutr 113:1811-1818. (Pubitemid 13024431)
17. Tompkins GR, O'Dell NL, Bryson IT, Pennington CB (2001) The effects of dietary ferric iron and iron deprivation on the bacterial composition of the mouse intestine. Curr Microbiol 43:38-42. (Pubitemid 32549923)
18. Nemeth E, et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090-2093. (Pubitemid 40007660)
19. Farrow EG, Davis SI, Summers LJ, White KE (2009) Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20:955-960.
20. Farrow E, et al. (2010) Altered renal FGF23-mediated activity involving MAPK and Wnt: Effects of the Hyp mutation. J Endocrinol 207:67-75.
21. Kasai K, Hori MT, Goodman WG (1990) Characterization of the transferrin receptor in UMR-106-01 osteoblast-like cells. Endocrinology 126:1742-1749. (Pubitemid 20095787)
22. Kasai K, Hori MT, Goodman WG (1991) Transferrin enhances the antiproliferative effect of aluminum on osteoblast-like cells. Am J Physiol 260:E537-E543.
23. Kim BS, et al. (2002) Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death. Cell Immunol 220:96-106.
24. Warnecke C, et al. (2003) Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 17:1186-1188.
25. Semenza GL, et al. (1997) Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51:553-555. (Pubitemid 27088174)
26. Liu S, et al. (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291:E38-E49. (Pubitemid 44035308)
27. Tenenhouse HS, Econs MJ (2001) Mendelian Hypophosphatemias. The Metabolic and Molecular Bases of Inherited Disease, ed Valle D (McGraw-Hill, New York), pp 1-9.
28. Jonsson KB, et al. (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663. (Pubitemid 36459471)
29. Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-1234. (Pubitemid 37294915)
30. Yamazaki Y, et al. (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/ osteomalacia. J Clin Endocrinol Metab 87:4957-4960. (Pubitemid 35316332)
31. Larsson T, et al. (2004) Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094. (Pubitemid 38829975)
32. Yuan B, Meudt J, Blank R, Feng J, Drezner M (2010) Hexa-D-arginine reversal of osteoblast 7B2 dysregulation in Hyp-mice normalizes the HYP biochemical phenotype. J Bone Miner Res 25 (Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= c5c1b1c6-9d98-4ec8-bafa-833ec5088097. Accessed October 3, 2011.
33. Tenenhouse HS (2005) Regulation of phosphorus homeostasis by the type iia na/phosphate cotransporter. Annu Rev Nutr 25:197-214.
34. Portale AA, Halloran BP, Morris RC, Jr. (1989) Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 83:1494-1499. (Pubitemid 19124102)
35. Shimada T, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435. (Pubitemid 38787398)
36. Marie PJ, Glorieux FH (1983) Relation between hypomineralized periosteocytic lesions and bone mineralization in vitamin D-resistant rickets. Calcif Tissue Int 35:443-448. (Pubitemid 13028610)
37. Sato K, et al. (1997) Saccharated ferric oxide (SFO)-induced osteomalacia: In vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone 21:57-64. (Pubitemid 27341739)
38. Sato K, Shiraki M (1998) Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy. Endocr J 45:431-439. (Pubitemid 28477653)
39. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, oule SG (2009)) FGF23 elevation and hypophosphataemia following intravenous iron polymaltose - a prospective study. J Clin Endocrinol Metab 94:2332-2337.
40. Schouten BJ, Doogue MP, Soule SG, Hunt PJ (2009) Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 46:167-169.
41. Shimizu Y, et al. (2009) Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: Another form of FGF23-related hypophosphatemia. Bone 45:814-816.
42. Peyssonnaux C, et al. (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117:1926-1932. (Pubitemid 47036326)
43. Cutler C, Bravo A, Ray AD, Watt RK (2005) Iron loading into ferritin can be stimulated or inhibited by the presence of cations and anions: A specific role for phosphate. J Inorg Biochem 99:2270-2275. (Pubitemid 41727916)
44. Sitara D, et al. (2004) Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432. (Pubitemid 39576657)
45. Allen MR, et al. (2010) Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcif Tissue Int 86:67-71.
46. Parfitt AM, et al.; Report of the ASBMR Histomorphometry Nomenclature Committee (1987) Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
47. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408. (Pubitemid 34164012)
48. Larsson T, et al. (2005) Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146:3883-3891. (Pubitemid 41178968)